Global Subcutaneous Injector Market
Global Subcutaneous Injector Market

Subcutaneous Injector Comprehensive Study by Type (Fillable, Prefilled), Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Others), Medication (Liquid, Depot), Usability (Reusable, Disposable), End User (Hospital, Clinic, Laboratory, Others) Players and Region - Global Market Outlook to 2024

Subcutaneous Injector Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 14.8%  

Jun 2019 Edition 245 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Subcutaneous Injector Market Overview:
Subcutaneous injectors are bolus injector that utilized for medications and administer drugs. It also employed with several vaccines and medication such as insulin, goserelin and diacetylmorphine. Subcutaneous injectors market is expected to mark significant growth over forecasted period due to communicable diseases and technological advancement. There has been significant rise in number of people affected with neonatal deaths, infant deaths and neurological impairment with figure stood up to 70%, 36% and 25-50% in United States alone, so the application of Subcutaneous injectors market is expected to growing. The major companies are adding more proven technologies systematically and strategically in Asia-Pacific countries as these countries are focused on curing prevalence of chronic diseases. According to AMA, the Global Subcutaneous Injector market is expected to see growth rate of 14.8% and may see market size of USD24376.0 Million by 2024.

Market Drivers
  • Growing Prevalence of Chronic Diseases has Boosted the Subcutaneous Injector Market.
  • Rapid Demand of Self-Injection Device Fuelled up the Market.

Market Trend
  • Collaboration and Tie Up Of Leading Players
  • Innovation and Technology in the Field of Subcutaneous Injector Market.

Restraints
  • High Cost Associated With Subcutaneous Injector Device.
  • Lack of Awareness Hampers the Subcutaneous Injector Market.

Opportunities
  • Proliferation of Vaccinations and Biosimilar Leads to Grow the Subcutaneous Injector Market.
  • Upsurge Demand of Subcutaneous Injector in Emerging Market.

Challenges
  • Limitation Due to Alternative Mode of Drug Delivery are Anticipated to Challenge the Market.
  • Government Rules And Regulations Fluctuate The Market.


Competitive Landscape:
In subcutaneous injector market, it has been observed that most of the companies are upgrading or introducing different techniques such as patient convenience, potential for self-administration, better therapy adherence and reduced healthcare costs, the concept is steadily gaining traction within the healthcare industry.
Some of the key players profiled in the report are Antares Pharma Inc. (United States), Endo International PLC. (Ireland), PharmaJet Inc. (United States), Bioject Medical Technologies Inc. (United States), Medical International Technology Inc. (Canada), National Medical Products Inc. (United States) and Valeritas Holdings Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like European Pharma Group Ltd. (The Netherlands), PenJet Corporation (The Netherlands) and Crossject SA (France). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Subcutaneous Injector market by 2024. Considering Market by Medication, the sub-segment i.e. Liquid will boost the Subcutaneous Injector market. Considering Market by Usability, the sub-segment i.e. Reusable will boost the Subcutaneous Injector market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Subcutaneous Injector market.

Market Highlights:

“In February 2018, AMAG Pharmaceuticals, Inc. announced that U.S. Food and Drug Administration (FDA) approved the Makena subcutaneous auto-injector which is beneficial in providing treatment to reduce the risk of preterm birth in women pregnant with one baby. It also offers new administration option for patients and providers and contains a shorter, thinner non-visible needle compared to the intramuscular (IM) Makena injection.”

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Subcutaneous Injector market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Subcutaneous Injector market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Subcutaneous Injector Manufacturers, Subcutaneous Injector Traders, End-Use Market Participants of Different Segments of Subcutaneous Injector, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Fillable
  • Prefilled
By Application
  • Vaccine Delivery
  • Insulin Delivery
  • Oncology
  • Pain Management
  • Others
By Medication
  • Liquid
  • Depot

By Usability
  • Reusable
  • Disposable

By End User
  • Hospital
  • Clinic
  • Laboratory
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Chronic Diseases has Boosted the Subcutaneous Injector Market.
      • 3.2.2. Rapid Demand of Self-Injection Device Fuelled up the Market.
    • 3.3. Market Challenges
      • 3.3.1. Limitation Due to Alternative Mode of Drug Delivery are Anticipated to Challenge the Market.
      • 3.3.2. Government Rules And Regulations Fluctuate The Market.
    • 3.4. Market Trends
      • 3.4.1. Collaboration and Tie Up Of Leading Players
      • 3.4.2. Innovation and Technology in the Field of Subcutaneous Injector Market.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Subcutaneous Injector, by Type, Application, Medication, Usability, End User and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Subcutaneous Injector (Value)
      • 5.2.1. Global Subcutaneous Injector by: Type (Value)
        • 5.2.1.1. Fillable
        • 5.2.1.2. Prefilled
      • 5.2.2. Global Subcutaneous Injector by: Application (Value)
        • 5.2.2.1. Vaccine Delivery
        • 5.2.2.2. Insulin Delivery
        • 5.2.2.3. Oncology
        • 5.2.2.4. Pain Management
        • 5.2.2.5. Others
      • 5.2.3. Global Subcutaneous Injector by: Medication (Value)
        • 5.2.3.1. Liquid
        • 5.2.3.2. Depot
      • 5.2.4. Global Subcutaneous Injector by: Usability (Value)
        • 5.2.4.1. Reusable
        • 5.2.4.2. Disposable
      • 5.2.5. Global Subcutaneous Injector by: End User (Value)
        • 5.2.5.1. Hospital
        • 5.2.5.2. Clinic
        • 5.2.5.3. Laboratory
        • 5.2.5.4. Others
      • 5.2.6. Global Subcutaneous Injector Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Subcutaneous Injector (Volume)
      • 5.3.1. Global Subcutaneous Injector by: Type (Volume)
        • 5.3.1.1. Fillable
        • 5.3.1.2. Prefilled
      • 5.3.2. Global Subcutaneous Injector by: Application (Volume)
        • 5.3.2.1. Vaccine Delivery
        • 5.3.2.2. Insulin Delivery
        • 5.3.2.3. Oncology
        • 5.3.2.4. Pain Management
        • 5.3.2.5. Others
      • 5.3.3. Global Subcutaneous Injector by: Medication (Volume)
        • 5.3.3.1. Liquid
        • 5.3.3.2. Depot
      • 5.3.4. Global Subcutaneous Injector by: Usability (Volume)
        • 5.3.4.1. Reusable
        • 5.3.4.2. Disposable
      • 5.3.5. Global Subcutaneous Injector by: End User (Volume)
        • 5.3.5.1. Hospital
        • 5.3.5.2. Clinic
        • 5.3.5.3. Laboratory
        • 5.3.5.4. Others
      • 5.3.6. Global Subcutaneous Injector Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Subcutaneous Injector (Price)
      • 5.4.1. Global Subcutaneous Injector by: Type (Price)
  • 6. Subcutaneous Injector: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Antares Pharma Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Endo International PLC. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PharmaJet Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bioject Medical Technologies Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medical International Technology Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. National Medical Products Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Valeritas Holdings Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Subcutaneous Injector Sale, by Type, Application, Medication, Usability, End User and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Subcutaneous Injector (Value)
      • 7.2.1. Global Subcutaneous Injector by: Type (Value)
        • 7.2.1.1. Fillable
        • 7.2.1.2. Prefilled
      • 7.2.2. Global Subcutaneous Injector by: Application (Value)
        • 7.2.2.1. Vaccine Delivery
        • 7.2.2.2. Insulin Delivery
        • 7.2.2.3. Oncology
        • 7.2.2.4. Pain Management
        • 7.2.2.5. Others
      • 7.2.3. Global Subcutaneous Injector by: Medication (Value)
        • 7.2.3.1. Liquid
        • 7.2.3.2. Depot
      • 7.2.4. Global Subcutaneous Injector by: Usability (Value)
        • 7.2.4.1. Reusable
        • 7.2.4.2. Disposable
      • 7.2.5. Global Subcutaneous Injector by: End User (Value)
        • 7.2.5.1. Hospital
        • 7.2.5.2. Clinic
        • 7.2.5.3. Laboratory
        • 7.2.5.4. Others
      • 7.2.6. Global Subcutaneous Injector Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Subcutaneous Injector (Volume)
      • 7.3.1. Global Subcutaneous Injector by: Type (Volume)
        • 7.3.1.1. Fillable
        • 7.3.1.2. Prefilled
      • 7.3.2. Global Subcutaneous Injector by: Application (Volume)
        • 7.3.2.1. Vaccine Delivery
        • 7.3.2.2. Insulin Delivery
        • 7.3.2.3. Oncology
        • 7.3.2.4. Pain Management
        • 7.3.2.5. Others
      • 7.3.3. Global Subcutaneous Injector by: Medication (Volume)
        • 7.3.3.1. Liquid
        • 7.3.3.2. Depot
      • 7.3.4. Global Subcutaneous Injector by: Usability (Volume)
        • 7.3.4.1. Reusable
        • 7.3.4.2. Disposable
      • 7.3.5. Global Subcutaneous Injector by: End User (Volume)
        • 7.3.5.1. Hospital
        • 7.3.5.2. Clinic
        • 7.3.5.3. Laboratory
        • 7.3.5.4. Others
      • 7.3.6. Global Subcutaneous Injector Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Subcutaneous Injector (Price)
      • 7.4.1. Global Subcutaneous Injector by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Subcutaneous Injector: by Type(USD Million)
  • Table 2. Subcutaneous Injector Fillable , by Region USD Million (2013-2018)
  • Table 3. Subcutaneous Injector Prefilled , by Region USD Million (2013-2018)
  • Table 4. Subcutaneous Injector: by Application(USD Million)
  • Table 5. Subcutaneous Injector Vaccine Delivery , by Region USD Million (2013-2018)
  • Table 6. Subcutaneous Injector Insulin Delivery , by Region USD Million (2013-2018)
  • Table 7. Subcutaneous Injector Oncology , by Region USD Million (2013-2018)
  • Table 8. Subcutaneous Injector Pain Management , by Region USD Million (2013-2018)
  • Table 9. Subcutaneous Injector Others , by Region USD Million (2013-2018)
  • Table 10. Subcutaneous Injector: by Medication(USD Million)
  • Table 11. Subcutaneous Injector Liquid , by Region USD Million (2013-2018)
  • Table 12. Subcutaneous Injector Depot , by Region USD Million (2013-2018)
  • Table 13. Subcutaneous Injector: by Usability(USD Million)
  • Table 14. Subcutaneous Injector Reusable , by Region USD Million (2013-2018)
  • Table 15. Subcutaneous Injector Disposable , by Region USD Million (2013-2018)
  • Table 16. Subcutaneous Injector: by End User(USD Million)
  • Table 17. Subcutaneous Injector Hospital , by Region USD Million (2013-2018)
  • Table 18. Subcutaneous Injector Clinic , by Region USD Million (2013-2018)
  • Table 19. Subcutaneous Injector Laboratory , by Region USD Million (2013-2018)
  • Table 20. Subcutaneous Injector Others , by Region USD Million (2013-2018)
  • Table 21. South America Subcutaneous Injector, by Country USD Million (2013-2018)
  • Table 22. South America Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 23. South America Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 24. South America Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 25. South America Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 26. South America Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 27. Brazil Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 28. Brazil Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 29. Brazil Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 30. Brazil Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 31. Brazil Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 32. Argentina Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 33. Argentina Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 34. Argentina Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 35. Argentina Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 36. Argentina Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 37. Rest of South America Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 38. Rest of South America Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 39. Rest of South America Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 40. Rest of South America Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 41. Rest of South America Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 42. Asia Pacific Subcutaneous Injector, by Country USD Million (2013-2018)
  • Table 43. Asia Pacific Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 44. Asia Pacific Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 45. Asia Pacific Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 46. Asia Pacific Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 47. Asia Pacific Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 48. China Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 49. China Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 50. China Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 51. China Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 52. China Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 53. Japan Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 54. Japan Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 55. Japan Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 56. Japan Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 57. Japan Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 58. India Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 59. India Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 60. India Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 61. India Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 62. India Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 63. South Korea Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 64. South Korea Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 65. South Korea Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 66. South Korea Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 67. South Korea Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 68. Taiwan Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 69. Taiwan Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 70. Taiwan Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 71. Taiwan Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 72. Taiwan Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 73. Australia Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 74. Australia Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 75. Australia Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 76. Australia Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 77. Australia Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 78. Rest of Asia-Pacific Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 79. Rest of Asia-Pacific Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 80. Rest of Asia-Pacific Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 81. Rest of Asia-Pacific Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 82. Rest of Asia-Pacific Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 83. Europe Subcutaneous Injector, by Country USD Million (2013-2018)
  • Table 84. Europe Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 85. Europe Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 86. Europe Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 87. Europe Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 88. Europe Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 89. Germany Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 90. Germany Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 91. Germany Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 92. Germany Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 93. Germany Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 94. France Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 95. France Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 96. France Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 97. France Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 98. France Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 99. Italy Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 100. Italy Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 101. Italy Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 102. Italy Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 103. Italy Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 104. United Kingdom Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 105. United Kingdom Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 106. United Kingdom Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 107. United Kingdom Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 108. United Kingdom Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 109. Netherlands Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 110. Netherlands Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 111. Netherlands Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 112. Netherlands Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 113. Netherlands Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 114. Rest of Europe Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 115. Rest of Europe Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 116. Rest of Europe Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 117. Rest of Europe Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 118. Rest of Europe Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 119. MEA Subcutaneous Injector, by Country USD Million (2013-2018)
  • Table 120. MEA Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 121. MEA Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 122. MEA Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 123. MEA Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 124. MEA Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 125. Middle East Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 126. Middle East Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 127. Middle East Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 128. Middle East Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 129. Middle East Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 130. Africa Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 131. Africa Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 132. Africa Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 133. Africa Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 134. Africa Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 135. North America Subcutaneous Injector, by Country USD Million (2013-2018)
  • Table 136. North America Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 137. North America Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 138. North America Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 139. North America Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 140. North America Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 141. United States Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 142. United States Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 143. United States Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 144. United States Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 145. United States Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 146. Canada Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 147. Canada Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 148. Canada Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 149. Canada Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 150. Canada Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 151. Mexico Subcutaneous Injector, by Type USD Million (2013-2018)
  • Table 152. Mexico Subcutaneous Injector, by Application USD Million (2013-2018)
  • Table 153. Mexico Subcutaneous Injector, by Medication USD Million (2013-2018)
  • Table 154. Mexico Subcutaneous Injector, by Usability USD Million (2013-2018)
  • Table 155. Mexico Subcutaneous Injector, by End User USD Million (2013-2018)
  • Table 156. Subcutaneous Injector Sales: by Type(L Units)
  • Table 157. Subcutaneous Injector Sales Fillable , by Region L Units (2013-2018)
  • Table 158. Subcutaneous Injector Sales Prefilled , by Region L Units (2013-2018)
  • Table 159. Subcutaneous Injector Sales: by Application(L Units)
  • Table 160. Subcutaneous Injector Sales Vaccine Delivery , by Region L Units (2013-2018)
  • Table 161. Subcutaneous Injector Sales Insulin Delivery , by Region L Units (2013-2018)
  • Table 162. Subcutaneous Injector Sales Oncology , by Region L Units (2013-2018)
  • Table 163. Subcutaneous Injector Sales Pain Management , by Region L Units (2013-2018)
  • Table 164. Subcutaneous Injector Sales Others , by Region L Units (2013-2018)
  • Table 165. Subcutaneous Injector Sales: by Medication(L Units)
  • Table 166. Subcutaneous Injector Sales Liquid , by Region L Units (2013-2018)
  • Table 167. Subcutaneous Injector Sales Depot , by Region L Units (2013-2018)
  • Table 168. Subcutaneous Injector Sales: by Usability(L Units)
  • Table 169. Subcutaneous Injector Sales Reusable , by Region L Units (2013-2018)
  • Table 170. Subcutaneous Injector Sales Disposable , by Region L Units (2013-2018)
  • Table 171. Subcutaneous Injector Sales: by End User(L Units)
  • Table 172. Subcutaneous Injector Sales Hospital , by Region L Units (2013-2018)
  • Table 173. Subcutaneous Injector Sales Clinic , by Region L Units (2013-2018)
  • Table 174. Subcutaneous Injector Sales Laboratory , by Region L Units (2013-2018)
  • Table 175. Subcutaneous Injector Sales Others , by Region L Units (2013-2018)
  • Table 176. South America Subcutaneous Injector Sales, by Country L Units (2013-2018)
  • Table 177. South America Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 178. South America Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 179. South America Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 180. South America Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 181. South America Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 182. Brazil Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 183. Brazil Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 184. Brazil Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 185. Brazil Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 186. Brazil Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 187. Argentina Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 188. Argentina Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 189. Argentina Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 190. Argentina Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 191. Argentina Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 192. Rest of South America Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 193. Rest of South America Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 194. Rest of South America Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 195. Rest of South America Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 196. Rest of South America Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 197. Asia Pacific Subcutaneous Injector Sales, by Country L Units (2013-2018)
  • Table 198. Asia Pacific Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 199. Asia Pacific Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 200. Asia Pacific Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 201. Asia Pacific Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 202. Asia Pacific Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 203. China Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 204. China Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 205. China Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 206. China Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 207. China Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 208. Japan Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 209. Japan Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 210. Japan Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 211. Japan Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 212. Japan Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 213. India Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 214. India Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 215. India Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 216. India Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 217. India Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 218. South Korea Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 219. South Korea Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 220. South Korea Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 221. South Korea Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 222. South Korea Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 223. Taiwan Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 224. Taiwan Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 225. Taiwan Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 226. Taiwan Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 227. Taiwan Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 228. Australia Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 229. Australia Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 230. Australia Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 231. Australia Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 232. Australia Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 233. Rest of Asia-Pacific Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 234. Rest of Asia-Pacific Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 235. Rest of Asia-Pacific Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 236. Rest of Asia-Pacific Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 237. Rest of Asia-Pacific Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 238. Europe Subcutaneous Injector Sales, by Country L Units (2013-2018)
  • Table 239. Europe Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 240. Europe Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 241. Europe Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 242. Europe Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 243. Europe Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 244. Germany Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 245. Germany Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 246. Germany Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 247. Germany Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 248. Germany Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 249. France Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 250. France Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 251. France Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 252. France Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 253. France Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 254. Italy Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 255. Italy Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 256. Italy Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 257. Italy Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 258. Italy Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 259. United Kingdom Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 260. United Kingdom Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 261. United Kingdom Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 262. United Kingdom Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 263. United Kingdom Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 264. Netherlands Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 265. Netherlands Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 266. Netherlands Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 267. Netherlands Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 268. Netherlands Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 269. Rest of Europe Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 270. Rest of Europe Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 271. Rest of Europe Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 272. Rest of Europe Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 273. Rest of Europe Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 274. MEA Subcutaneous Injector Sales, by Country L Units (2013-2018)
  • Table 275. MEA Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 276. MEA Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 277. MEA Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 278. MEA Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 279. MEA Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 280. Middle East Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 281. Middle East Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 282. Middle East Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 283. Middle East Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 284. Middle East Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 285. Africa Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 286. Africa Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 287. Africa Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 288. Africa Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 289. Africa Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 290. North America Subcutaneous Injector Sales, by Country L Units (2013-2018)
  • Table 291. North America Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 292. North America Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 293. North America Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 294. North America Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 295. North America Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 296. United States Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 297. United States Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 298. United States Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 299. United States Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 300. United States Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 301. Canada Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 302. Canada Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 303. Canada Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 304. Canada Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 305. Canada Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 306. Mexico Subcutaneous Injector Sales, by Type L Units (2013-2018)
  • Table 307. Mexico Subcutaneous Injector Sales, by Application L Units (2013-2018)
  • Table 308. Mexico Subcutaneous Injector Sales, by Medication L Units (2013-2018)
  • Table 309. Mexico Subcutaneous Injector Sales, by Usability L Units (2013-2018)
  • Table 310. Mexico Subcutaneous Injector Sales, by End User L Units (2013-2018)
  • Table 311. Subcutaneous Injector: by Type(USD/Units)
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Subcutaneous Injector: by Type(USD Million)
  • Table 320. Subcutaneous Injector Fillable , by Region USD Million (2019-2024)
  • Table 321. Subcutaneous Injector Prefilled , by Region USD Million (2019-2024)
  • Table 322. Subcutaneous Injector: by Application(USD Million)
  • Table 323. Subcutaneous Injector Vaccine Delivery , by Region USD Million (2019-2024)
  • Table 324. Subcutaneous Injector Insulin Delivery , by Region USD Million (2019-2024)
  • Table 325. Subcutaneous Injector Oncology , by Region USD Million (2019-2024)
  • Table 326. Subcutaneous Injector Pain Management , by Region USD Million (2019-2024)
  • Table 327. Subcutaneous Injector Others , by Region USD Million (2019-2024)
  • Table 328. Subcutaneous Injector: by Medication(USD Million)
  • Table 329. Subcutaneous Injector Liquid , by Region USD Million (2019-2024)
  • Table 330. Subcutaneous Injector Depot , by Region USD Million (2019-2024)
  • Table 331. Subcutaneous Injector: by Usability(USD Million)
  • Table 332. Subcutaneous Injector Reusable , by Region USD Million (2019-2024)
  • Table 333. Subcutaneous Injector Disposable , by Region USD Million (2019-2024)
  • Table 334. Subcutaneous Injector: by End User(USD Million)
  • Table 335. Subcutaneous Injector Hospital , by Region USD Million (2019-2024)
  • Table 336. Subcutaneous Injector Clinic , by Region USD Million (2019-2024)
  • Table 337. Subcutaneous Injector Laboratory , by Region USD Million (2019-2024)
  • Table 338. Subcutaneous Injector Others , by Region USD Million (2019-2024)
  • Table 339. South America Subcutaneous Injector, by Country USD Million (2019-2024)
  • Table 340. South America Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 341. South America Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 342. South America Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 343. South America Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 344. South America Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 345. Brazil Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 346. Brazil Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 347. Brazil Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 348. Brazil Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 349. Brazil Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 350. Argentina Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 351. Argentina Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 352. Argentina Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 353. Argentina Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 354. Argentina Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 355. Rest of South America Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 356. Rest of South America Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 357. Rest of South America Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 358. Rest of South America Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 359. Rest of South America Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 360. Asia Pacific Subcutaneous Injector, by Country USD Million (2019-2024)
  • Table 361. Asia Pacific Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 362. Asia Pacific Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 363. Asia Pacific Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 364. Asia Pacific Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 365. Asia Pacific Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 366. China Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 367. China Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 368. China Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 369. China Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 370. China Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 371. Japan Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 372. Japan Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 373. Japan Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 374. Japan Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 375. Japan Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 376. India Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 377. India Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 378. India Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 379. India Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 380. India Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 381. South Korea Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 382. South Korea Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 383. South Korea Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 384. South Korea Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 385. South Korea Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 386. Taiwan Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 387. Taiwan Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 388. Taiwan Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 389. Taiwan Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 390. Taiwan Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 391. Australia Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 392. Australia Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 393. Australia Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 394. Australia Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 395. Australia Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 396. Rest of Asia-Pacific Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 397. Rest of Asia-Pacific Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 398. Rest of Asia-Pacific Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 399. Rest of Asia-Pacific Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 400. Rest of Asia-Pacific Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 401. Europe Subcutaneous Injector, by Country USD Million (2019-2024)
  • Table 402. Europe Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 403. Europe Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 404. Europe Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 405. Europe Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 406. Europe Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 407. Germany Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 408. Germany Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 409. Germany Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 410. Germany Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 411. Germany Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 412. France Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 413. France Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 414. France Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 415. France Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 416. France Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 417. Italy Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 418. Italy Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 419. Italy Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 420. Italy Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 421. Italy Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 422. United Kingdom Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 423. United Kingdom Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 424. United Kingdom Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 425. United Kingdom Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 426. United Kingdom Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 427. Netherlands Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 428. Netherlands Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 429. Netherlands Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 430. Netherlands Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 431. Netherlands Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 432. Rest of Europe Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 433. Rest of Europe Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 434. Rest of Europe Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 435. Rest of Europe Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 436. Rest of Europe Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 437. MEA Subcutaneous Injector, by Country USD Million (2019-2024)
  • Table 438. MEA Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 439. MEA Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 440. MEA Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 441. MEA Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 442. MEA Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 443. Middle East Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 444. Middle East Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 445. Middle East Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 446. Middle East Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 447. Middle East Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 448. Africa Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 449. Africa Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 450. Africa Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 451. Africa Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 452. Africa Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 453. North America Subcutaneous Injector, by Country USD Million (2019-2024)
  • Table 454. North America Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 455. North America Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 456. North America Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 457. North America Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 458. North America Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 459. United States Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 460. United States Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 461. United States Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 462. United States Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 463. United States Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 464. Canada Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 465. Canada Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 466. Canada Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 467. Canada Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 468. Canada Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 469. Mexico Subcutaneous Injector, by Type USD Million (2019-2024)
  • Table 470. Mexico Subcutaneous Injector, by Application USD Million (2019-2024)
  • Table 471. Mexico Subcutaneous Injector, by Medication USD Million (2019-2024)
  • Table 472. Mexico Subcutaneous Injector, by Usability USD Million (2019-2024)
  • Table 473. Mexico Subcutaneous Injector, by End User USD Million (2019-2024)
  • Table 474. Subcutaneous Injector Sales: by Type(L Units)
  • Table 475. Subcutaneous Injector Sales Fillable , by Region L Units (2019-2024)
  • Table 476. Subcutaneous Injector Sales Prefilled , by Region L Units (2019-2024)
  • Table 477. Subcutaneous Injector Sales: by Application(L Units)
  • Table 478. Subcutaneous Injector Sales Vaccine Delivery , by Region L Units (2019-2024)
  • Table 479. Subcutaneous Injector Sales Insulin Delivery , by Region L Units (2019-2024)
  • Table 480. Subcutaneous Injector Sales Oncology , by Region L Units (2019-2024)
  • Table 481. Subcutaneous Injector Sales Pain Management , by Region L Units (2019-2024)
  • Table 482. Subcutaneous Injector Sales Others , by Region L Units (2019-2024)
  • Table 483. Subcutaneous Injector Sales: by Medication(L Units)
  • Table 484. Subcutaneous Injector Sales Liquid , by Region L Units (2019-2024)
  • Table 485. Subcutaneous Injector Sales Depot , by Region L Units (2019-2024)
  • Table 486. Subcutaneous Injector Sales: by Usability(L Units)
  • Table 487. Subcutaneous Injector Sales Reusable , by Region L Units (2019-2024)
  • Table 488. Subcutaneous Injector Sales Disposable , by Region L Units (2019-2024)
  • Table 489. Subcutaneous Injector Sales: by End User(L Units)
  • Table 490. Subcutaneous Injector Sales Hospital , by Region L Units (2019-2024)
  • Table 491. Subcutaneous Injector Sales Clinic , by Region L Units (2019-2024)
  • Table 492. Subcutaneous Injector Sales Laboratory , by Region L Units (2019-2024)
  • Table 493. Subcutaneous Injector Sales Others , by Region L Units (2019-2024)
  • Table 494. South America Subcutaneous Injector Sales, by Country L Units (2019-2024)
  • Table 495. South America Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 496. South America Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 497. South America Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 498. South America Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 499. South America Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 500. Brazil Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 501. Brazil Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 502. Brazil Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 503. Brazil Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 504. Brazil Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 505. Argentina Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 506. Argentina Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 507. Argentina Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 508. Argentina Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 509. Argentina Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 510. Rest of South America Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 511. Rest of South America Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 512. Rest of South America Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 513. Rest of South America Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 514. Rest of South America Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 515. Asia Pacific Subcutaneous Injector Sales, by Country L Units (2019-2024)
  • Table 516. Asia Pacific Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 517. Asia Pacific Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 518. Asia Pacific Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 519. Asia Pacific Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 520. Asia Pacific Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 521. China Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 522. China Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 523. China Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 524. China Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 525. China Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 526. Japan Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 527. Japan Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 528. Japan Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 529. Japan Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 530. Japan Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 531. India Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 532. India Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 533. India Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 534. India Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 535. India Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 536. South Korea Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 537. South Korea Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 538. South Korea Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 539. South Korea Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 540. South Korea Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 541. Taiwan Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 542. Taiwan Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 543. Taiwan Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 544. Taiwan Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 545. Taiwan Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 546. Australia Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 547. Australia Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 548. Australia Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 549. Australia Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 550. Australia Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 551. Rest of Asia-Pacific Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 552. Rest of Asia-Pacific Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 553. Rest of Asia-Pacific Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 554. Rest of Asia-Pacific Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 555. Rest of Asia-Pacific Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 556. Europe Subcutaneous Injector Sales, by Country L Units (2019-2024)
  • Table 557. Europe Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 558. Europe Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 559. Europe Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 560. Europe Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 561. Europe Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 562. Germany Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 563. Germany Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 564. Germany Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 565. Germany Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 566. Germany Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 567. France Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 568. France Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 569. France Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 570. France Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 571. France Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 572. Italy Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 573. Italy Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 574. Italy Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 575. Italy Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 576. Italy Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 577. United Kingdom Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 578. United Kingdom Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 579. United Kingdom Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 580. United Kingdom Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 581. United Kingdom Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 582. Netherlands Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 583. Netherlands Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 584. Netherlands Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 585. Netherlands Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 586. Netherlands Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 587. Rest of Europe Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 588. Rest of Europe Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 589. Rest of Europe Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 590. Rest of Europe Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 591. Rest of Europe Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 592. MEA Subcutaneous Injector Sales, by Country L Units (2019-2024)
  • Table 593. MEA Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 594. MEA Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 595. MEA Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 596. MEA Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 597. MEA Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 598. Middle East Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 599. Middle East Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 600. Middle East Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 601. Middle East Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 602. Middle East Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 603. Africa Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 604. Africa Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 605. Africa Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 606. Africa Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 607. Africa Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 608. North America Subcutaneous Injector Sales, by Country L Units (2019-2024)
  • Table 609. North America Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 610. North America Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 611. North America Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 612. North America Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 613. North America Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 614. United States Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 615. United States Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 616. United States Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 617. United States Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 618. United States Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 619. Canada Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 620. Canada Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 621. Canada Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 622. Canada Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 623. Canada Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 624. Mexico Subcutaneous Injector Sales, by Type L Units (2019-2024)
  • Table 625. Mexico Subcutaneous Injector Sales, by Application L Units (2019-2024)
  • Table 626. Mexico Subcutaneous Injector Sales, by Medication L Units (2019-2024)
  • Table 627. Mexico Subcutaneous Injector Sales, by Usability L Units (2019-2024)
  • Table 628. Mexico Subcutaneous Injector Sales, by End User L Units (2019-2024)
  • Table 629. Subcutaneous Injector: by Type(USD/Units)
  • Table 630. Research Programs/Design for This Report
  • Table 631. Key Data Information from Secondary Sources
  • Table 632. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Subcutaneous Injector: by Type USD Million (2013-2018)
  • Figure 5. Global Subcutaneous Injector: by Application USD Million (2013-2018)
  • Figure 6. Global Subcutaneous Injector: by Medication USD Million (2013-2018)
  • Figure 7. Global Subcutaneous Injector: by Usability USD Million (2013-2018)
  • Figure 8. Global Subcutaneous Injector: by End User USD Million (2013-2018)
  • Figure 9. South America Subcutaneous Injector Share (%), by Country
  • Figure 10. Asia Pacific Subcutaneous Injector Share (%), by Country
  • Figure 11. Europe Subcutaneous Injector Share (%), by Country
  • Figure 12. MEA Subcutaneous Injector Share (%), by Country
  • Figure 13. North America Subcutaneous Injector Share (%), by Country
  • Figure 14. Global Subcutaneous Injector: by Type L Units (2013-2018)
  • Figure 15. Global Subcutaneous Injector: by Application L Units (2013-2018)
  • Figure 16. Global Subcutaneous Injector: by Medication L Units (2013-2018)
  • Figure 17. Global Subcutaneous Injector: by Usability L Units (2013-2018)
  • Figure 18. Global Subcutaneous Injector: by End User L Units (2013-2018)
  • Figure 19. South America Subcutaneous Injector Share (%), by Country
  • Figure 20. Asia Pacific Subcutaneous Injector Share (%), by Country
  • Figure 21. Europe Subcutaneous Injector Share (%), by Country
  • Figure 22. MEA Subcutaneous Injector Share (%), by Country
  • Figure 23. North America Subcutaneous Injector Share (%), by Country
  • Figure 24. Global Subcutaneous Injector: by Type USD/Units (2013-2018)
  • Figure 25. Global Subcutaneous Injector share by Players 2018 (%)
  • Figure 26. Global Subcutaneous Injector share by Players (Top 3) 2018(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. Antares Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Antares Pharma Inc. (United States) Revenue: by Geography 2018
  • Figure 30. Endo International PLC. (Ireland) Revenue, Net Income and Gross profit
  • Figure 31. Endo International PLC. (Ireland) Revenue: by Geography 2018
  • Figure 32. PharmaJet Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. PharmaJet Inc. (United States) Revenue: by Geography 2018
  • Figure 34. Bioject Medical Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bioject Medical Technologies Inc. (United States) Revenue: by Geography 2018
  • Figure 36. Medical International Technology Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 37. Medical International Technology Inc. (Canada) Revenue: by Geography 2018
  • Figure 38. National Medical Products Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. National Medical Products Inc. (United States) Revenue: by Geography 2018
  • Figure 40. Valeritas Holdings Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Valeritas Holdings Inc. (United States) Revenue: by Geography 2018
  • Figure 42. Global Subcutaneous Injector: by Type USD Million (2019-2024)
  • Figure 43. Global Subcutaneous Injector: by Application USD Million (2019-2024)
  • Figure 44. Global Subcutaneous Injector: by Medication USD Million (2019-2024)
  • Figure 45. Global Subcutaneous Injector: by Usability USD Million (2019-2024)
  • Figure 46. Global Subcutaneous Injector: by End User USD Million (2019-2024)
  • Figure 47. South America Subcutaneous Injector Share (%), by Country
  • Figure 48. Asia Pacific Subcutaneous Injector Share (%), by Country
  • Figure 49. Europe Subcutaneous Injector Share (%), by Country
  • Figure 50. MEA Subcutaneous Injector Share (%), by Country
  • Figure 51. North America Subcutaneous Injector Share (%), by Country
  • Figure 52. Global Subcutaneous Injector: by Type L Units (2019-2024)
  • Figure 53. Global Subcutaneous Injector: by Application L Units (2019-2024)
  • Figure 54. Global Subcutaneous Injector: by Medication L Units (2019-2024)
  • Figure 55. Global Subcutaneous Injector: by Usability L Units (2019-2024)
  • Figure 56. Global Subcutaneous Injector: by End User L Units (2019-2024)
  • Figure 57. South America Subcutaneous Injector Share (%), by Country
  • Figure 58. Asia Pacific Subcutaneous Injector Share (%), by Country
  • Figure 59. Europe Subcutaneous Injector Share (%), by Country
  • Figure 60. MEA Subcutaneous Injector Share (%), by Country
  • Figure 61. North America Subcutaneous Injector Share (%), by Country
  • Figure 62. Global Subcutaneous Injector: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Antares Pharma Inc. (United States)
  • Endo International PLC. (Ireland)
  • PharmaJet Inc. (United States)
  • Bioject Medical Technologies Inc. (United States)
  • Medical International Technology Inc. (Canada)
  • National Medical Products Inc. (United States)
  • Valeritas Holdings Inc. (United States)
Additional players considered in the study are as follows:
European Pharma Group Ltd. (The Netherlands) , PenJet Corporation (The Netherlands) , Crossject SA (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation